天智航(688277) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥51,750,233.99, representing a year-over-year increase of 121.92%[5] - The net loss attributable to shareholders for Q3 2023 was ¥-35,182,926.97, with a year-to-date loss of ¥-72,081,373.89[5] - The year-to-date revenue increased by 58.63%, driven by enhanced product development and market expansion in orthopedic surgical robots and related products[10] - Total operating revenue for the first three quarters of 2023 reached CNY 133,666,408.30, a significant increase from CNY 84,265,045.11 in the same period of 2022, representing a growth of approximately 58.7%[21] - The net profit for Q3 2023 was CNY -76,992,237.38, an improvement compared to CNY -87,757,969.44 in Q3 2022, reflecting a reduction in losses of approximately 12.7%[22] - The company reported a total comprehensive loss of CNY -76,751,026.99 for Q3 2023, compared to CNY -86,961,665.96 in Q3 2022, indicating a reduction in comprehensive losses of about 11.5%[23] Research and Development - Research and development expenses totaled ¥33,221,968.52 for Q3 2023, accounting for 64.20% of revenue, a decrease of 58.84 percentage points compared to the same period last year[6][11] - Research and development expenses for Q3 2023 totaled CNY 86,558,662.46, up from CNY 80,328,845.46 in Q3 2022, marking an increase of about 7.6%[22] Assets and Equity - Total assets increased by 16.08% from the end of the previous year, reaching ¥1,633,143,635.62[6] - The total assets as of Q3 2023 were CNY 1,633,143,635.62, compared to CNY 1,406,958,245.52 in the previous year, showing a growth of approximately 16.1%[19] - The total equity attributable to shareholders increased by 26.46% year-over-year, amounting to ¥1,319,852,190.68[6] - The company's equity attributable to shareholders reached CNY 1,319,852,190.68 in Q3 2023, up from CNY 1,043,692,867.62 in Q3 2022, representing a growth of approximately 26.4%[19] Cash Flow - The company reported cash flow from operating activities of ¥-154,368,489.65 for the year-to-date period[6] - The net cash flow from operating activities for the first three quarters of 2023 was -¥154,368,489.65, worsening from -¥129,972,334.28 in the same period of 2022[26] - The total cash inflow from financing activities in the first three quarters of 2023 was ¥532,089,990.23, significantly higher than ¥25,716,192.23 in the same period of 2022[27] - The net cash flow from financing activities for the first three quarters of 2023 was ¥507,601,760.70, compared to only ¥7,217,957.74 in the same period of 2022[27] - The cash and cash equivalents at the end of the third quarter of 2023 amounted to ¥379,372,553.95, an increase from ¥168,038,447.01 at the end of the same period in 2022[27] - The company experienced a net increase in cash and cash equivalents of ¥168,189,404.75 in the first three quarters of 2023, contrasting with a decrease of -¥119,074,138.07 in the same period of 2022[27] Inventory and Receivables - The company's inventory decreased to RMB 38,304,190.88 from RMB 43,804,172.55, a decline of about 12.5%[17] - The company reported an increase in other receivables to RMB 18,319,066.11 from RMB 11,854,982.74, representing a growth of approximately 54.3%[17] Market Activity - The company performed over 16,000 surgeries using its orthopedic surgical robot from January to September 2023, marking a year-on-year increase of over 70%[15] - The orthopedic surgical robot has been routinely used in over 180 hospitals, with a cumulative total of over 50,000 surgeries performed[15] - The company received a medical device registration certificate for its knee joint replacement surgical navigation system, enhancing its product offerings and competitive edge[15] Investments - The long-term equity investments increased significantly to RMB 91,795,823.51 from RMB 22,045,007.35 at the end of 2022, reflecting a growth of approximately 316.5%[17] - The cash inflow from investment activities in the first three quarters of 2023 was ¥49,857,237.97, a decrease from ¥242,089,118.30 in the same period of 2022[26] - The cash outflow from investment activities in the first three quarters of 2023 was ¥235,944,938.84, slightly lower than ¥241,609,836.92 in the same period of 2022[26] - The company received cash from the recovery of investments amounting to ¥47,234,156.31 in the first three quarters of 2023, down from ¥226,045,467.80 in the same period of 2022[26] - The company reported a cash inflow from tax refunds of ¥13,380,434.00, compared to ¥7,961,803.15 in the same period of 2022[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,878[13] - The top ten shareholders held a significant portion of shares, with the largest shareholder owning 16.84%[13]